Jonat W - Search Results

1

Effect of continuous vs intermittent application of 3-OH-tamoxifen or tamoxifen on the proliferation of the human breast cancer cell line MCF-7 M1.

Dietel M, Löser R, Röhlke P, Jonat W, Niendorf A, Gerding D, Kohr A, Hölzel F, Arps H. Dietel M, et al. Among authors: jonat w. J Cancer Res Clin Oncol. 1989;115(1):36-40. doi: 10.1007/BF00391597. J Cancer Res Clin Oncol. 1989. PMID: 2921271

2

p53 is a persistent and predictive marker in advanced ovarian carcinomas: multivariate analysis including comparison with Ki67 immunoreactivity.

Röhlke P, Milde-Langosch K, Weyland C, Pichlmeier U, Jonat W, Löning T. Röhlke P, et al. Among authors: jonat w. J Cancer Res Clin Oncol. 1997;123(9):496-501. doi: 10.1007/BF01192204. J Cancer Res Clin Oncol. 1997. PMID: 9341899

3

Transforming growth factor beta 2 (TGF-beta 2) levels in plasma of patients with metastatic breast cancer treated with tamoxifen.

Kopp A, Jonat W, Schmahl M, Knabbe C. Kopp A, et al. Among authors: jonat w. Cancer Res. 1995 Oct 15;55(20):4512-5. Cancer Res. 1995. PMID: 7553618

4

Aromatase inhibition with 4-hydroxyandrostenedione in the treatment of postmenopausal patients with advanced breast cancer: a phase II study.

Höffken K, Jonat W, Possinger K, Kölbel M, Kunz T, Wagner H, Becher R, Callies R, Friederich P, Willmanns W, et al. Höffken K, et al. Among authors: jonat w. J Clin Oncol. 1990 May;8(5):875-80. doi: 10.1200/JCO.1990.8.5.875. J Clin Oncol. 1990. PMID: 2185341 Clinical Trial.

5

Reverse transcriptase/polymerase chain reaction detection of cytokeratin-19 mRNA in bone marrow and blood of breast cancer patients.

Krüger W, Krzizanowski C, Holweg M, Stockschläder M, Kröger N, Jung R, Mross K, Jonat W, Zander AR. Krüger W, et al. Among authors: jonat w. J Cancer Res Clin Oncol. 1996;122(11):679-86. doi: 10.1007/BF01209032. J Cancer Res Clin Oncol. 1996. PMID: 8898979

6

Overexpression of p53 and prognosis in breast cancer.

Friedrichs K, Gluba S, Eidtmann H, Jonat W. Friedrichs K, et al. Among authors: jonat w. Cancer. 1993 Dec 15;72(12):3641-7. doi: 10.1002/1097-0142(19931215)72:12<3641::aid-cncr2820721215>3.0.co;2-8. Cancer. 1993. PMID: 8252480

7

Regulation and role of TGF beta production in breast cancer.

Knabbe C, Kopp A, Hilgers W, Lang D, Müller V, Zugmaier G, Jonat W. Knabbe C, et al. Among authors: jonat w. Ann N Y Acad Sci. 1996 Apr 30;784:263-76. doi: 10.1111/j.1749-6632.1996.tb16241.x. Ann N Y Acad Sci. 1996. PMID: 8651574

8

Combined treatment with TRAIL and PPARγ ligands overcomes chemoresistance of ovarian cancer cell lines.

Bräutigam K, Biernath-Wüpping J, Bauerschlag DO, von Kaisenberg CS, Jonat W, Maass N, Arnold N, Meinhold-Heerlein I. Bräutigam K, et al. Among authors: jonat w. J Cancer Res Clin Oncol. 2011 May;137(5):875-86. doi: 10.1007/s00432-010-0952-2. Epub 2010 Sep 29. J Cancer Res Clin Oncol. 2011. PMID: 20878528

9

Estrogen receptor status and adjuvant polychemotherapy or antiestrogen therapy in patients with high-risk breast cancer.

Jonat W, Maass H, Braun M, Winter G. Jonat W, et al. J Cancer Res Clin Oncol. 1984;107(3):233-7. doi: 10.1007/BF01032614. J Cancer Res Clin Oncol. 1984. PMID: 6736112

10

New trends in the endocrine treatment of breast cancer.

Maass H, Jonat W, Eidtmann H, Kunz T, Kügler G. Maass H, et al. Among authors: jonat w. Recent Results Cancer Res. 1990;118:225-32. doi: 10.1007/978-3-642-83816-3_21. Recent Results Cancer Res. 1990. PMID: 2146726 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

266 results

Search Page

Filters